ClinicalTrials.gg
RecruitingNCT05037760Updated Feb 5, 2026

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

A Phase 2 interventional study of Elritercept and Ruxolitinib in Myelofibrosis, sponsored by Takeda. Recruiting at 46 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Primary Myelofibrosis with a site in Italy — 24 open to participants now, 43 under way, 11 of them phase 3. Primary Myelofibrosis · Italy.

Planned enrollment
39th of 83
135 · median 121
Started
2021
with 14 others
Phase 2
27 of 101
4 open now
Primary completion
2028-02
later than 27 of 42 live
Registered
73rd of 101
by date

Among the 101 studies in Primary Myelofibrosis with a site in Italy, this one is the 39th largest by planned enrollment of the 83 interventional ones that give a count, is one of 15 that started in 2021, is one of 27 in phase 2, reaches primary completion later than 27 of the 42 other live ones, and was the 73rd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

24 of the 101 studies in Primary Myelofibrosis with a site in Italy are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Primary Myelofibrosis with a site in Italy, or all of them as a file.
02

Study summary

The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.

Read the detailed description

Elritercept is an investigational therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in participants with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

03

Conditions studied

  • Myelofibrosis

Keywords

  • Thrombocytopenia
  • Anemia
  • Red blood cells
  • Bone marrow
  • KER-050
  • drug therapy
  • elritercept
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information in accordance with national and local study participant privacy regulations.
  2. In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits).
  3. Male or female greater than equal to (≥)18 years of age, at the time of signing informed consent.
  4. (ECOG) performance score lesser than equal to (≤)2.
  5. ≥12 months per Investigator assessment.
  6. Confirmed diagnosis of primary myelofibrosis (PMF) (prefibrotic or overtly fibrotic) according to the 2016 World Health Organization (WHO) criteria, post-polycythemia vera myelofibrosis (PV MF), or post-essential thrombocythemia myelofibrosis (ET MF) according to the 2008 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria.
  7. Anemia, defined as:

    1. Having received ≥6 units of RBC transfusion for ≤8.5 g/dL in the 12 weeks prior to the planned C1D1, including ≥1 unit of RBC transfusion in the 28 days prior to C1D1; or
    2. Having ≥3 evaluable Hgb measurements at less than (\<)10.0 g/dL including ≥1 evaluable Hgb measurement assessed 8 to 13 weeks prior to C1D1. Participants receiving RBC transfusions but not meeting criterion "a." may enroll under criterion "b." following the below parameters:

      • All pre-transfusion Hgb values (defined as a Hgb assessed within the 3 days prior to a transfusion) should be recorded, and ≥1 pre-transfusion Hgb value is required.
      • Hgb values collected within the 28 days following a transfusion will not be considered evaluable unless qualifying as a pre-transfusion Hgb; in cases where multiple transfusions are given in succession due to poor Hgb response, only the first pre-transfusion Hgb will be considered evaluable.
  8. Arm-specific criteria:

    Arms 1A and 2A:

    1. Previously treated with JAK inhibitor(s) and, per the Investigator, discontinued due to one of the following reasons:

      • disease following treatment with JAK inhibitor(s)
      • Refractory to treatment with JAK inhibitor(s)
      • Intolerance to treatment with JAK inhibitor(s)
      • Participant no longer met risk/benefit ratio to continue JAK inhibitor(s) OR
      • Participant with prognostic score of intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) and is ineligible for JAK inhibitor(s) in the opinion of the Investigator
    2. Participants previously treated with JAK inhibitor(s) must have discontinued JAK inhibitor therapy ≥8 weeks before C1D1

    Arms 1B and 2B:

    1. Has been receiving ruxolitinib prescribed for a diagnosis of PMF (prefibrotic or overtly fibrotic), post-PV MF, or post-ET MF for ≥8 weeks prior to C1D1 and on a stable dose for ≥4 weeks prior to C1D1. In Arm 2B only, at least 10 participants should have been on ruxolitinib for \<6 months prior to C1D1.
    2. Meets ≥1 of the following criteria in the opinion of the Investigator:

      • Current ruxolitinib treatment is considered to be providing insufficient control of the disease
      • The participant's cytopenias are limiting the participant's ruxolitinib dose intensity
      • The participant's disease is symptomatic and warrants additional therapy

    Arm 2C (Brazil only):

    1. No prior treatment with JAK inhibitor(s) and no access to JAK inhibitor therapy as determined by the Investigator
    2. Spleen volume ≥ 450 cubic centimeter (cm\^3) as assessed by CT or MRI collected during the pretreatment period and/or
    3. Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF-TSS) meeting at least one of the following criteria during the pretreatment period:

      • 2 symptoms with average score ≥ 3
      • Average total symptom score ≥ 10
  9. Females of and sexually active males must agree to use highly effective methods of as described in the protocol.

Exclusion criteria

Exclusion Criteria:

Medical History:

  1. Active infection requiring parenteral antibiotic therapy within 28 days prior to C1D1 or oral antibiotics within 14 days of C1D1. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  2. Presence of the following cardiac conditions:

    1. Class 3 or 4 heart failure
    2. (QT interval corrected by Fridericia's formula) >500 milliseconds (msec) on the screening or C1D1 (ECG; mean of 3 measurements)
    3. Uncontrolled arrhythmia (participants with rate-controlled atrial fibrillation are not excluded)
    4. Acute myocardial infarction or unstable angina pectoris ≤6 months prior to C1D1
  3. (BMI) ≥40 kilograms per meter square (kg/m\^2).
  4. Presence of uncontrolled hypertension, defined as systolic blood pressure ≥160 millimeters of mercury (mmHg) or diastolic blood pressure ≥100 mmHg despite adequate treatment.
  5. History of drug or alcohol abuse (as defined by the Investigator) within the past 2 years.
  6. History of stroke, deep venous thrombosis, or arterial embolism within 6 months prior to C1D1.
  7. Major surgery within 28 days prior to C1D1. Participants must have completely recovered from any previous surgery prior to C1D1 in the opinion of the Investigator.
  8. Known positive for (HIV), active infectious with positive viral load (hepatitis B virus [HBV] deoxyribonucleic acid [DNA]), or active infectious with positive viral load (hepatitis C virus [HCV] ribonucleic acid [RNA]). Participants without a known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  9. Any other than PMF, post-ET MF, or post-PV MF that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or biologic therapy, within 1 year prior to C1D1. In situ cancers, squamous cell and basal cell carcinomas, and monoclonal gammopathy of unclear significance are allowed at the discretion of the Investigator.
  10. History of solid organ or hematological transplantation.
  11. History of severe allergic or anaphylactic reaction(s) or to recombinant proteins or in the drug, or ruxolitinib for participants enrolling in Arm 1B or 2B.
  12. Diagnosis of hemolytic anemia, active bleeding, hemoglobinopathies, or congenital disorders as a cause of the participant's anemia.
  13. History of intracranial hemorrhage (any grade).
  14. National Cancer Institute (NCI) (CTCAE) Grade ≥2 bleeding events within the 3 months prior to C1D1.
  15. Receipt of an RBC or transfusion for any reason(s) or combination of reasons other than underlying MF within the 12 weeks prior to C1D1. If a participant requires a transfusion for an unanticipated reason during the Pretreatment Period, a prolonged screening period may be considered after discussion with the Medical Monitor.

    Treatment History:

  16. Prior treatment with luspatercept, sotatercept, or other commercially available or investigational transforming growth factor-beta (TGF-β) inhibitors (all arms).
  17. Treatment within 28 days prior to C1D1 with:

    1. Erythropoiesis-stimulating agent (ESA)
    2. Granulocyte colony-stimulating factor (G-CSF)
    3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
    4. Thrombopoietin (TPO) agonists
    5. Immunomodulator imide drugs (IMiDs) (e.g., thalidomide, pomalidomide, lenalidomide)
    6. Interferon
    7. Hydroxyurea
    8. at doses exceeding corticosteroid equivalent of 10 mg/day prednisone
  18. Newly initiated iron chelation therapy within the 8 weeks prior to C1D1. Stable doses of iron chelators are allowed if prescribed per label.
  19. Vitamin B12 and/or folate therapy initiated within 4 weeks before randomization. Participants on stable replacement doses for ≥4 weeks and without concurrent vitamin B12 or folate deficiency are allowed.
  20. Treatment with another investigational drug or device or approved therapy for the treatment of MF or anemia in MF ≤28 days prior to C1D1, or, if the half-life of the previous product is known, within 5 times the half-life prior to C1D1, whichever is longer.
  21. For Arms 1B and 2B (participants receiving ruxolitinib), initiation of treatment with strong cytochrome P450 (CYP)3A4 inhibitors within 2 weeks prior to C1D1. Participants receiving inhibitors/inducers as concomitant therapy with ruxolitinib in accordance with ruxolitinib local prescribing information may continue to receive such therapies in this study.

    Laboratory Exclusions (during screening):

  22. Bone marrow aspirate blast percentage >5 percent (%)

    a. In the event of a non-evaluable pretreatment bone marrow aspirate expected to be due to marrow fibrosis, participants may be enrolled without bone marrow aspirate blast percentage data if all other eligibility criteria are met. Historical bone marrow data may be requested to support confirmation of diagnosis.

  23. Peripheral blood blast percentage ≥10%
  24. Platelet count \<25 × 10\^9 per liter (10\^9/)L or >450 × 10\^9/L
  25. Persistent \<7 g/dL despite RBC transfusions
  26. Transferrin saturation \<15%
  27. Ferritin \<50 nanograms per mililiters (ng/mL)
  28. Folate \<4.5 nanomoles per liter (nmol/L) (\<2.0 picograms per liter (pg/L))
  29. Vitamin B12 \<148 picomoles per liter (pmol/L) (\<200 picograms per milliliter (pg/mL))
  30. Estimated \<30 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) (as determined by the Chronic Kidney Disease Epidemiology Collaboration equation)
  31. (AST) or Alanine aminotransferase (ALT) >3 × (ULN)
  32. Total >2 × ULN
  33. (INR) >1.2 × ULN, unless participant is receiving anticoagulation, in which instance the INR must fall within the participant's designated therapeutic range.

    Miscellaneous:

  34. Pregnant or lactating females.
  35. Any other condition not specifically noted above that, in the opinion of the Investigator or Sponsor, would preclude the participant from participating in the study.
  36. Participants who are investigational site staff members directly involved in the conduct of the study and their immediate family members, site staff members otherwise supervised by the Investigator, or participants who are Keros or contract research organization (CRO) employees directly involved in the conduct of the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Arm 1A: Elritercept

    Participants with anemia who have discontinued Janus Kinase (JAK) inhibitor(s) or are intolerant or ineligible for JAK inhibitor(s) will be administered escalating doses of elritercept, starting at 0.75 milligrams per kilograms (mg/kg) followed by 1.5 mg/kg and 4.5 mg/kg subcutaneously (SC), every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.

    Drug: Elritercept

  • Experimental
    Arm 1B: Elritercept + Ruxolitinib

    Participants with anemia who have been receiving ruxolitinib for ≥8 weeks prior to Cycle 1 Day 1 (C1D1) and are on a stable dose for ≥4 weeks prior to C1D1 will be administered escalating doses of elritercept, starting at 0.75 mg/kg and followed by 1.5 mg/kg and 4.5 mg/kg, SC, every 4 weeks for 13 cycles in combination with ruxolitinib therapy for a total Treatment Period of 52 weeks. Each cycle is 28 days.

    Drug: Elritercept · Drug: Ruxolitinib

  • Experimental
    Arm 2A: Elritercept

    Participants with with anemia who have discontinued JAK inhibitor(s) or are intolerant or ineligible for JAK inhibitor(s) will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.

    Drug: Elritercept

  • Experimental
    Arm 2B: Elritercept + Ruxolitinib

    Participants with anemia who have been receiving ruxolitinib for ≥8 weeks prior to C1D1 and are on a stable dose for ≥4 weeks prior to C1D1 will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles in combination with ruxolitinib therapy for a total Treatment Period of 52 weeks. Each cycle is 28 days.

    Drug: Elritercept · Drug: Ruxolitinib

  • Experimental
    Experimental: Arm 2C: Elritercept (Brazil Only)

    Participants from Brazil with anemia who have received no prior treatment with JAK inhibitor(s) and have no access to JAK inhibitor therapy will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.

    Drug: Elritercept

  • Experimental
    Long-Term Extension

    Participants from Arms 1A, 1B, 2A, 2B and 2C benefiting from the continued elritercept treatment as a monotherapy or in combination with ruxolitinib can continue to receive elritercept in this long-term extension phase until elritercept becomes commercially available or until elritercept is no longer being developed for the treatment of MF.

    Drug: Elritercept · Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs), Dose Limiting Toxicities (DLTs), Severe Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE:any untoward medical occurrence (MO) in clinical study participant administered medicinal product not necessarily having causal relationship with treatment.Severe AE medically significant AE but not immediately life-threatening;may result in hospitalization/ prolonged hospital stay;disability.SAE:any untoward MO that,at any dose results in death,is life-threatening,requires in-patient hospitalization/ prolongation of existing hospitalization,results in persistent or significant disability/incapacity,is congenital anomaly/birth defect,is medically important event.DLT: any following safety events-death,Grade 4 neutropenia/ thrombocytopenia \>7 days,Grade 3 thrombocytopenia with bleeding,Neutropenic fever,assessments meeting Hy's law,Grade ≥3 nonhematologic treatment-emergent adverse events(TEAEs),elevated hemoglobin(Hgb)/ platelet count requiring dose modification, other safety event considered by Safety Review Committee(SRC) to be significant to warrant categorization as DLT.

    Time frame: From signing of the informed consent form (ICF) through 30 days after the last dose of study drug (approximately 8 years)

  2. Part 2 and Long-Term Extension: Number of Participants with Adverse Events (AEs), Severe AEs and SAEs

    An AE is defined as any untoward medical occurrence in a clinical study participant administered a medicinal product that does not necessarily have a causal relationship with this treatment. Severe AE is defined as an AE which is medically significant but not immediately life-threatening; may result in hospitalization or prolonged hospital stay; disabling. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: From signing of the ICF through 30 days after the last dose of study drug, (approximately 8 years)

Secondary outcomes

  1. Percentage of Participants with Progression to Acute Myeloid Leukemia (AML)

    Time frame: From signing of the ICF through 30 days after the last dose of study drug, (approximately 8 years)

  2. Percentage of Participants with Progression to Accelerated MF

    Time frame: From signing of the ICF through 30 days after the last dose of study drug, (approximately 8 years)

  3. Percentage of Participants with Red Blood Cell (RBC) Transfusion Independence Over a Period of ≥12 Consecutive Weeks

    Participants with anemia requiring RBC transfusions will be assessed for this outcome measure.

    Time frame: Up to Week 24

  4. Percentage of Participants with RBC Transfusions From Baseline Over a Period of ≥12 Consecutive Weeks

    Participants with anemia requiring RBC transfusions will be assessed for this outcome measure and percentage of participants with ≥50% decrease in number of RBC transfusions will be represented.

    Time frame: Up to Week 24

  5. Percentage of Participants with Mean Haemoglobin (Hgb) Increase From Baseline Over a Period of ≥12 Consecutive Weeks

    Participants with transfusion-independence will be assessed for this outcome measure for mean Hgb ≥1.5 grams per deciliter (g/dL) and ≥2.0 g/dL.

    Time frame: Up to Week 24

  6. Percentage of Participants with Improvement in the Myelofibrosis Symptom Assessment Form Version 4.0 Total Symptom Score (MF-SAF(v4.0)-TSS) From Baseline at Week 24

    Percentage of participants with MF-SAF(v4.0)-TSS of ≥50% will be presented for this assessment. MF-SAF v4.0 captures participant self-report of 7 core MF symptoms (this includes fatigue, night sweats, itching, abdominal discomfort, pain under ribs on left side, early satiety, and bone pain) over the past 7 days. Response options range from 0 (absent) to 10 (worst imaginable). The TSS is computed by averaging the individual item responses and multiplying by 7 for a weekly total score ranging from 0 to 70. Higher scores represent higher symptom burden.

    Time frame: Week 24

  7. Percentage of Participants with Decrease in Spleen Volume From Baseline as Measured by Computed Tomography/Magnetic Resonance Imaging (CT/MRI) at Week 24

    Percentage of participants with decrease in spleen volume of ≥35% will be presented for this outcome measure.

    Time frame: Week 24

  8. Plasma Concentrations of Elritercept

    Time frame: Within 2 hours before administration of elritercept at multiple timepoints up to 8 weeks after the end of treatment

  9. Maximum Observed Serum Concentration (Cmax) of Elritercept

    Time frame: Within 2 hours before administration of elritercept at multiple timepoints up to 8 weeks after the end of treatment

  10. Time to Maximum Observed Concentration (Tmax) of Elritercept

    Time frame: Within 2 hours before administration of elritercept at multiple timepoints up to 8 weeks after the end of treatment

  11. Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-last) of Elritercept

    Time frame: Through Cycle 1 (each cycle=28 days)

  12. Minimum Observed Serum Concentration (Cmin) of Elritercept

    Time frame: Within 2 hours before administration of elritercept at multiple timepoints up to 8 weeks after the end of treatment

  13. Accumulation Rate (Rac) of Elritercept

    Time frame: Within 2 hours before administration of elritercept at multiple timepoints up to 8 weeks after the end of treatment

  14. Change From Baseline in Red Cell Parameters

    The red cell parameters including reticulocyte count, Hgb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and reticulocyte cell Hgb will be assessed.

    Time frame: At multiple timepoints from pre-treatment period up to 8 weeks after end of treatment

07

Study locations

39 of 46 sites recruiting
  • Concord Hospital
    Concord, New South Wales, Australia
    Recruiting
    • Site Contact · Contact
    • Ilona Cunningham · Principal investigator
  • The Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
    Recruiting
    • Site Contact · Contact
    • Steven Wong · Principal investigator
  • Flinders Medical Centre
    Woodville South, South Australia 5042, Australia
    Recruiting
    • Site Contact · Contact
    • David Ross · Principal investigator
  • St. Vincents Hospital Melbourne
    Fitzroy, Victoria 3355, Australia
    Recruiting
    • Site Contact · Contact
    • Shuhying Tan · Principal investigator
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
    Recruiting
    • Site Contact · Contact
    • Lynette Chee · Principal investigator
  • Ballarat Oncology & Haematology Service
    Wendouree, Victoria 3355, Australia
    Recruiting
    • Site Contact · Contact
    • George Kannourakis · Principal investigator
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Brazil
    Recruiting
    • Site Contact · Contact
    • Laura Maria Fogliatto · Principal investigator
  • IMV-Pesquisa Cardiologica Sociedade Simples
    Porto Alegre, Brazil
    Recruiting
    • Site Contact · Contact
    • Marcelo Capra · Principal investigator
  • Albert Einstein Sociedade Beneficente Israelita Brasiliera
    São Paulo, Brazil
    Recruiting
    • Site Contact · Contact
    • Nelson Hamerschlak · Principal investigator
  • Hospital Beneficencia Portuguesa de Sao Paulo
    São Paulo, Brazil
    Recruiting
    • Site Contact · Contact
    • Fabio Pires de Souza Santos · Principal investigator
  • Hospital Das Clinicas Da Faculdade de Medicina Da U S P
    São Paulo, Brazil
    Recruiting
    • Site Contact · Contact
    • Fernanda Salles Seguro · Principal investigator
  • Instituto de Ensino e Pesquisas Sao Lucas
    São Paulo, Brazil
    Recruiting
    • Site Contact · Contact
    • Rodrigo Santucci Alves da Silva · Principal investigator
  • CHU Amiens - Hopital Sud
    Amiens, France
    Completed

    Not enrolling at this site — choose another above.

  • Hopital Morvan
    Brest, France
    Completed

    Not enrolling at this site — choose another above.

  • Hopital Prive Sevigne
    Cesson-Sévigné, France
    Completed

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Lyon Sud
    Lyon, France
    Recruiting
    • Site Contact · Contact
    • Fiorenza Barraco · Principal investigator
  • Institut de Cancerologie du Gard
    Nîmes, France
    Recruiting
    • Site Contact · Contact
    • Stefan Wickenhauser · Principal investigator
  • Hopital de la Source - CHR Orleans
    Orléans, France
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    Bari, Italy
    Recruiting
    • Site Contact · Contact
    • Pellegrino Musto · Principal investigator
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, Italy
    Recruiting
    • Site Contact · Contact
    • Francesca Palandri · Principal investigator
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
    Brescia, Italy
    Recruiting
    • Site Contact · Contact
    • Mariella D'Adda · Principal investigator
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Italy
    Recruiting
    • Site Contact · Contact
    • Alessandro Maria Vannucchi · Principal investigator
  • Ospedale Policlinico San Martino
    Genova, Italy
    Recruiting
    • Site Contact · Contact
    • Marica Laurino · Principal investigator
  • ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center
    Milan, Italy
    Recruiting
    • Site Contact · Contact
    • Marianna Caramella · Principal investigator
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milan, Italy
    Recruiting
    • Site Contact · Contact
    • Alessandra Iurlo · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Milan, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
    Reggio Emilia, Italy
    Recruiting
    • Site Contact · Contact
    • Alessia Tieghi · Principal investigator
  • Azienda Ospedaliera Universitaria Policlinico Umberto I
    Roma, Italy
    Recruiting
    • Site Contact · Contact
    • Massimo Breccia · Principal investigator
  • Azienda Socio Sanitaria Territoriale Sette Laghi
    Varese, Italy
    Recruiting
    • Site Contact · Contact
    • Marco Brociner · Principal investigator
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, Italy
    Recruiting
    • Site Contact · Contact
    • Massimiliano Bonifacio · Principal investigator
  • Gachon University Gil Medical Center
    Incheon, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Samsung Medical Center
    Seoul, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Seoul St. Marys Hospital, The Catholic University of Korea
    Seoul, South Korea
    Recruiting
    • Site Contact · Contact
    • Sung-Eun Lee · Principal investigator
  • Soonchunhyang University Seoul Hospital
    Seoul, South Korea
    Recruiting
    • Site Contact · Contact
    • Jong-Ho Won · Principal investigator
  • ICO Badalona - Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
    Recruiting
    • Site Contact · Contact
    • Bianca Xicoy · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
    Recruiting
    • Site Contact · Contact
    • Maria Laura Fox · Principal investigator
  • Hospital Universitario La Paz
    Madrid, Spain
    Recruiting
    • Site Contact · Contact
    • Mercedes Gasior Kabat · Principal investigator
  • Hospital Universitario La Princesa
    Madrid, Spain
    Recruiting
    • Site Contact · Contact
    • Javier Loscertales · Principal investigator
  • Hospital Universitario de Salamanca
    Salamanca, Spain
    Recruiting
    • Site Contact · Contact
    • Jesus Maria Hernandez Rivas · Principal investigator
  • Hospital Clinico Universitario de Valencia
    Valencia, Spain
    Recruiting
    • Site Contact · Contact
    • Juan Carlos Juan Carlos Hernandez Boluda · Principal investigator
  • Hospital QuironSalud de Zaragoza
    Zaragoza, Spain
    Recruiting
    • Site Contact · Contact
    • Pilar Giraldo · Principal investigator
  • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
    Boston, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Ciro Rinaldi · Principal investigator
  • St James Hospital,Leeds
    Leeds, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Chun Huat Teh · Principal investigator
  • Guys Hospital
    London, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Jennifer O'Sullivan · Principal investigator
  • Hammersmith Hospital
    London, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Simone Claudiani · Principal investigator
  • University College London
    London, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Andrew Wilson · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Feb 2028, 74 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's planned 74 months is above that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Sep 8, 2021
StartActual
Dec 16, 2021
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2030
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05037760
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Dec 16, 2021
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Feb 5, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elritercept

Start the discussion